Tag:

Merck

Latest Headlines

Latest Headlines

Merck steps into Ebola vaccine race with NewLink rights deal

Merck has snapped up the exclusive rights to NewLink Genetics' Ebola vaccine, which is being rushed into a Phase III study as part of a global effort to head off an outbreak in West Africa.

Merck in talks with NewLink to scale up Ebola vaccine production: Bloomberg

Merck may soon be the next Big Pharma to step into the Ebola vaccine arena.

UPDATED: NewLink, Merck sign Ebola vaccine licensing pact

To scale up production of its Ebola vaccine, NewLink Genetics is going to need some manufacturing help. And for that, it's turning to vaccine giant Merck.

Merck's Zetia results inflame debate over statin prescribing

How low should LDL go? That is the debate that continues among heart doctors since the American Heart Association upended statin prescribing guidelines last year, and Merck's Zetia is now in the middle of the muddle.

Ex-Merck cancer R&D chief Gilliland takes the helm at Fred Hutch

The Fred Hutchinson Cancer Research Center has tapped well-known drug investigator Gary Gilliland to become its new president.

The U.K. is open for biotech business, and Merck is buying in

The U.K. is striving to brand itself as a hotbed for biotech R&D, promising new funds for startups, pledging to speed up its approval process and courting some major players to deepen their roots in the country.

Surprise: Merck's cholesterol combo Vytorin hits goal in long-awaited outcomes trial

Merck & Co.'s cholesterol drug Vytorin hit its goal in a long-awaited outcomes trial, beating solo statin therapy at cutting cardiovascular risk. It's a vindication for the company, which endured a storm of criticism about an earlier trial in which Vytorin fell short.

Merck JV signs on Bangladeshi firms to speed low-cost cholera candidate

When Merck's Indian JV, Hilleman Laboratories, teamed up in June with Swedish biotech Gotovax AB, the plan was to get an affordable cholera vaccine to the developing world. Just a few months out, it's inked a pact to make that happen faster.

Merck's head-to-head Vytorin trial might be surprisingly flattering

Merck & Co. just disclosed some welcome news for its own investors--and potentially for competitors, too. Not to mention all the market watchers ready for the long IMPROVE-IT trial saga to come to an end.

UPDATED: Merck's hepatitis C cocktail drug fails a 4-week challenge

After sending out signals that it might be running into trouble with a short-duration study of a new triple combination drug for its hepatitis C regimen, Merck investigators hailed the clear success of an 8-week test but confirmed analysts' fears in a batch of 4-week data released at the meeting of the American Association for the Study of Liver Diseases.